Northrop Grumman Corporation (NOC) Stock Price Today
Aura AI Summary
Key Stats
- $73.85BMarket Cap
- 1,311,209Volume
- IndustrialsSector
- $768.0252W High
- $473.4652W Low
- 83 DaysTypical Hold Time
- $87.83BEnterprise Value
- 1.9%Div Yield
- -Trading Activity
Track Northrop Grumman Corporation (NOC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Northrop Grumman Corporation has traded between a low of $473.46 and a high of $768.02, highlighting its annual price range. Buy and sell Northrop Grumman Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Most Recent News
Disc Medicine stock jumps 38% on positive Phase 3 trial and analyst upgrade
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...

Qualcomm exec sells 1,827 shares worth $319K under prearranged trading plan
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...

EyePoint shares plunge after DURAVYU fails Phase 3 trial for wet AMD, prompting major workforce cuts.
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.